HIV Clinical Trial
Official title:
A Phase IV, Open-label Three-arm Study Investigating the Impact of a Combination of Tenofovir Disoproxil Fumarate/Emtricitabine With Raltegravir or Dolutegravir or Elvitegravir/Cobicistat on Renal Tubular Function and Renal Transporters in HIV-1 Antiretroviral naïve Patients
The purpose of this study is to observe the safety of Truvada® (TDF/FTC) in relation to its
impact on kidney function combined with different Integrase Inhibitors (Dolutegravir, or
Elvitegravir/Cobicistat or Raltegravir), when given to patients who are commencing treatment
for HIV infection for the first time.
All three combinations (Raltegravir + Truvada®, Dolutegravir + Truvada® and Stribild®, a
single pill which contains Elvitegravir/Cobicistat/Truvada®) are currently recommended by
the national guide-lines and used in standard clinical practice.
The study will monitor kidney function, and compare the safety and effectiveness of Truvada®
when taken with Dolutegravir, or Elvitegravir/Cobicistat or Raltegravir, over the first 48
weeks of treatment in HIV-1 antiretrovirals naïve patients.
The safety and how well these drug combinations are tolerated will be determined based on
physical examinations, laboratory tests, and questions about any problems the participant
might experience during the study. As part of this trial, levels of HIV-1 in the blood and
urinary markers of kidney function and inflammatory markers will be measured at various
times during the study.
The total duration of participant involvement in the trial will be up to 48 weeks, with up
to 45 days between the screening and baseline visits. Participants will need to visit the
clinic 6 times within the 48 weeks.
Once participants have been confirmed to be eligible to participate in the study,
participants will attend for a baseline visit (day 1) where they will be randomly assigned
to receive one of the three treatments listed below:
- Treatment Arm 1: Stribild® (EVG/COBI/FTC/TDF) 1 tablet once a day
- Treatment Arm 2: Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® 1
tablet once a day
- Treatment Arm 3: Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® 1 tablet
once a day
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
| Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
| Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
| Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
| Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
| Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
| Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
| Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
| Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
| Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
| Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
| Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
| Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
| Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |